Background-Chemotherapy with trastuzumab and anthracycline is associated with incident heart failure (HF) in patients with breast cancer. We hypothesized that continuous incidental use of β-blocker agents (BB) was protective against HF in patients without established structural heart disease who were receiving trastuzumab and anthracycline. Methods and Results-We identified 920 consecutive patients with breast cancer (age 52.3±11.0 years) with normal ejection fraction before receiving trastuzumab and anthracycline therapy at our institution between 2005 and 2010. Using a propensity score and a greedy 5 to 1 digit-matching algorithm, 106 of these patients on continuous BB during cancer treatment were matched with 212 patients from the same pool with similar characteristics but not on continuous BB. During a median follow-up of 3.2±2.0 years, 32 incident HF admissions were identified in these 318 patients with breast cancer, whereas 28 cancer-related (noncardiac) deaths occurred before any incident HF. Cumulative incidence regression models and cause-specific hazards of new HF events were estimated from competing risk Cox models of time-dependent covariates. Although trastuzumab therapy showed significant association with incident HF, independent of anthracycline-related cardiotoxicity (hazard ratio, 9.0; 95% confidence interval, 3.0-27.0; P<0.0001), continuous use of BB was associated with lower risk of new HF events (hazard ratio, 0.2; 95% confidence interval, 0.1-0.5; P=0.003). Conclusions-Coincidental, continuous use of BB is associated with lower incidence of HF in patients with breast cancer and normal baseline ejection fraction in a competing risk framework, and after matching for demographics, clinical, and cancer-related treatment characteristics. Prospective randomized clinical trials to validate these findings are warranted. (Circ Heart Fail. 2013;6:420-426.)
P atients who survive cancer are at a higher risk of developing cardiovascular disease than recurrence of cancer, with heart-related complications representing a problem in up to 27% of patients who survive breast cancer, 1 a group which accounts for nearly a quarter of all cancer survivors. 2 The use of anthracycline and trastuzumab, especially in combination, pose a specific risk for the development of heart failure (HF) among patients with breast cancer and without overt structural heart disease at the time of cancer treatment. Although the effects of trastuzumab-related cardiotoxicity have been considered to be largely benign, short term, and reversible within a period of 2 to 4 months after discontinuation of treatment, 3 data have emerged raising concern for irreversible systolic dysfunction in up to 40% of patients treated with trastuzumab after anthracycline. 4, 5 
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Routine evaluation before and during trastuzumab therapy includes clinical evaluation for features of congestive HF, and monitoring of left ventricular (LV) function, usually based on ejection fraction (EF). [6] [7] [8] [9] However, the appropriate management of asymptomatic mild LV dysfunction in patients without known cardiovascular disease at the time of cancer treatment onset is unclear, given the variation inherent in EF measurement, there is a lot of uncertainty about how best to respond. The worst case scenario is that an EF fall is overestimated and leads to interruption of chemotherapy, with potential major implications for breast cancer prognosis. 10 An asymptomatic decrease in EF is an indication for therapy with β-blockers (BBs) in the management of HF in adults according to current guidelines, 11 but this approach is not yet generally accepted for primary prevention of cardiotoxicity. Indeed, although use of cardioprotective agents has been suggested, 12, 13 neither intentional nor coincidental continuous use of BBs during trastuzumab and chemotherapy treatment has yet been studied. Accordingly, we hypothesized that coincidental continuous use of BBs during chemotherapy with trastuzumab and anthracycline could reduce new HF events in patients who survive breast cancer without established structural heart disease. To address this hypothesis, we sought cardiotoxicity in a competing risk framework, accounting for noncardiac-related death (breast cancer), and independent of time-dependent incidental use of other potential cardio protective medication.
Methods

Study Participants
Participants were selected from 1807 consecutive female patients, ≥18 years, newly diagnosed and biopsy-confirmed with breast cancer (International Classification of Diseases, Ninth Revision diagnosis codes: 174.0, 174.1-174.9, 233.0, and V10.3). All patients had a baseline EF measurement. All were receiving chemotherapeutic regiments consisting of anthracycline (mean total dose of 268.3±163.7 mg), trastuzumab, or anthracycline followed by trastuzumab, with or without radiotherapy within the Cleveland Clinic Health System (CCHS) during the period 2005 to 2010. (Figure 1 )
Patients were excluded in the presence of other cancers, major comorbidity (kidney or heart transplant, dialysis, HF, chronic pulmonary heart disease, hypertrophic cardiomyopathy, valvular disease, and aortic aneurysm), and myocardial infarction before breast cancer diagnosis. Patients with hypertension, cerebrovascular disease, coronary artery disease, and cardiac dysrhythmias were included in the cohort only if they had normal ejection fraction at the time of initial treatment with chemotherapy and no structural heart disease.
Of the remaining 963 patients, 30 additional patients were excluded, because they were either diagnosed with cardiac disease within 30 to 60 days of the cancer biopsy diagnosis date or had baseline echocardiogram characteristics, suggesting cardiac pathology before starting chemotherapy. Another 13 patients were excluded, because of limited follow-up within the CCHS of <90 days, leaving a pool of 920 patients.
Using CCHS electronic health records (EHR), including medication lists provided at each chemotherapy or at other cancer-related visit, we identified a cohort of 106 patients taking continuous BBs during cancer therapy ( Table I in the online-only Data Supplement). These were matched 1:2 with 212 other patients with similar demographics, clinical, and treatment characteristics ( Figure 1 ), by using a propensity-matching technique to avoid BB treatment selection bias. Study entry date was set as the time of first visit for anthracycline chemotherapy; for those patients receiving only trastuzumab, entry date was defined as the first day of trastuzumab chemotherapy. All 318 patients were followed-up until either an incident HF event or death occurred, or until their last visit with a CCHS physician for patients with no outcomes. Follow-up was completed in June 2012.
All patient data were encrypted and deidentified before the statistical analyses, and the study was approved by the Cleveland Clinic (CCF) Institutional Review Board.
Exposure Variables and Covariates
The main exposure variable was BB therapy started at any time before the onset of chemotherapy, and uninterrupted during all cycles of chemotherapy treatment. BBs used included metoprolol, atenolol, carvedilol, propranolol, bisoprolol, labetalol, or nadolol. Exposure to uninterrupted BBs before and during the entire course of chemotherapy was categorized as yes or no. Trastuzumab was also considered an exposure variable. Criteria used for ascertainment of trastuzumab and anthracycline treatment were a minimum of 2 related visits confirmed in the CCF billing claims database. For continuous use of BBs during cancer therapy, medication lists available with every cancer-related procedure within Taussig Cancer Institute were the primary source. A second source was self-reported medication during echocardiographic visits before chemotherapy, when this information was available. Validation by an independent clinician was attempted from the patient medication lists in the EHR on any encounter with the CCF system.
The primary source for demographic and clinical variables was also EHR data entered by trained healthcare professionals for clinical purposes, at any time patients had an episode of care within the CCHS. Demographic variables, included self-reported race, marital status, county of residence, and zip code, used to estimate patient income and education level through neighborhood-aggregated census data. 14 Anthropometric characteristics (weight, height, and systolic and diastolic blood pressure) and HF risk factors (smoking status, Charlson score) 15 were determined based on clinical measurements done during the first chemotherapy visit by clinical nurses. Baseline LVEF, systolic, and diastolic function parameters used as exclusion criteria and to adjust for possible floor and ceiling effects were obtained from the baseline conventional 2-dimensional (2D) echocardiography using Simpson biplane technique, according to American Society of Echocardiography guidelines. 16 Medical history (hypertension, diabetes mellitus, cerebrovascular disease, coronary artery disease, chronic obstructive pulmonary disease, cardiac dysrhythmias), cancer therapy (chemotherapy combinations, tamoxifen, radiotherapy), and medication with potential cardioprotective properties (angiotensin-converting enzyme [ACE] inhibitors, statins, insulin, clopidogrel, aspirin) were followed longitudinally for the whole study period, by using the EHR.
Outcome
All admissions for HF or with mention of HF diagnosis were captured, evidenced by the International Classification of Diseases, Ninth Revision diagnosis codes (428.0, 428.1, 428.20-428.23, 428.30-428.33, 428.40-428.43, and 428.9). To maximize specificity, HF had to be associated with a hospital admission, and appear at least twice in the follow-up history, and be validated by a cardiologist by direct review of the EHR and echocardiogram. Any death precluding consideration of any subsequent new HF event was perceived as a competing risk. Those deaths were also collected from EHR and verified against the social security death index.
Data Quality
Data quality was optimized using standardized protocols of data extraction. Missing values for covariates (<10%), and outlier values were completed using multiple imputation techniques.
Statistical Analysis
Descriptive statistics including mean (SD), median (interquartile range), and frequencies for continuous and categorical variables were calculated in the entire cohort (n=920) and stratified by continuous BB therapy, using Pearson χ 2 and Wilcoxon rank sum for comparing differences between patients on continuous BB therapy and others. On the basis of clinical plausibility and those results, a nonparsimonious logistic regression model was built (Table II in the online-only Data  Supplement) to calculate a propensity score reflecting the probability of receiving continuous BB treatment, after linearity assumptions were relaxed by fitting the model using restricted cubic splines. To assure a highly inclusive model while maintaining statistical validity and providing good fit, potential risk factors were dropped, only when there was collinearity. Next, the propensity score index for receiving continuous BBs, derived by the logistical model (Table II in the online-only Data Supplement), was assigned to each patient and further used to match our 106 patients with uninterrupted BB treatment during cancer therapy with 212 controls, in an attempt to reduce differences between those 2 groups, and control for potential BB treatment-related selection bias. Propensity matching was done using a greedy 5 to 1 digit-matching algorithm technique 17 Descriptive features of the matched cohort, stratified by BB therapy groups, were compared to assess whether propensity score matching provided homogeneous groups in relation to demographic, clinical, and cancer-related covariates ( Table 1) . χ 2 tests for categorical covariates and general linear models for continuous variables were used for comparisons between continuous BB therapy and the rest of the cohort. Crude cumulative incidence function estimates were plotted as a step function, using the method of Fine and Gray, and used for a proportional hazard interpretation 18 to address both the association between trastuzumab and the cumulative incidence of new HF, independent of anthracycline treatment and continuous BB therapy, and cumulative incidence of new HF in the presence of noncardiac (breast cancer related) death as competing risk. Cox models were used to report cause-specific hazard (new HF) and competing noncardiac death (competing risk), by censoring patients with noncardiac death. The results were further validated with discrimination analysis proposed by Pencina and D'Agostino. 19 Standard statistical software (SAS version 9.2, SAS Institute, Cary, NC) was used to perform all analyses, and 2-tailed P values <0.05 were used to report statistical significance. 
Results
Baseline Characteristics
Baseline characteristics of the overall patient population with breast cancer, without overt structural heart disease and with normal ejection fraction at baseline (n=920), were stratified by continuous use of BBs during cancer chemotherapy, showing significant differences between those 2 groups ( Table I in the onlineonly Data Supplement). Patients on continuous BBs (n=106) were significantly older and different with respect to their demographic characteristics (higher proportion of nonwhites, more single women living in areas with lower median neighborhood income), comorbidities (higher prevalence of diabetes mellitus, hypertension, anxiety), and noncancer-related medication, when compared with their counterparts (n=814). Patients on continuous BB therapy also are more likely to have received anthracycline therapy than trastuzumab during follow-up period.
On the basis of these results, the best candidates variables were identified for a multivariate logistic regression model ( Table II in the online-only Data Supplement) computing a propensity score further used to match (1:2) the BB group (n=106) with controls (n=212) with similar demographics, clinical, and treatment characteristics. Baseline characteristics of the final cohort of 318 matched patients with breast cancer (Table 1) showed no significant differences between the matched groups, with the exception of residual differences in hypertension and related treatment at baseline (higher in BB group). The final cohort (n=318) had a mean age of 56.6±10.0 years, with the participation of 56% whites. Hypertension at baseline (39%) was the main cause of treatment with ACE inhibitors (20%) and diuretics (33%).
Events
Thirty-two patients (10%) developed new HF events during a median follow-up of 3.2±2.0 years, whereas other 28 patients (9%) died of noncardiac (cancer-related) causes ( Table 2) . No significant noncardiac-related mortality differences were shown between the BB treatment groups, but new HF events were significantly more common among patients without BBs (n=27; 12.7%) compared with patients on continuous BBs (n=5; 4.7%; Table 2 ). Table 3 and Figure 2 show the impact of continuous use of BBs during cancer therapy in patients with breast cancer on trastuzumab and anthracycline therapy, using 2 different methods addressing the risk of new HF but taking account of the competing risk of cancer-related mortality. BBs seem to be significantly protective with hazard ratios for HF of 0.2 (95% confidence interval [CI], 0.1-0.7); P=0.008 and estimated cumulative incidence of 0.25 (P<0.0005) over a 5-year period. Other covariates found to be associated with lower risks of incident HF in this cohort were age (hazard ratio [HR], 0.66 [95% CI, 0.46-0.96]; P=0.03 for every 10 years of age), being a lifetime nonsmoker (HR, 0.2 [95% CI, 0.1-0.6]; P=0.004), and coincidental use of statins (HR, 0.3 [95% CI, 0.1-0.9]; P=0.04).
Associations of New HF Events
Trastuzumab showed significant cardiotoxic risk, independent of anthracycline therapy with a HR of 9.5 (95% CI, 3.9-23.1); P<0.0001, when compared with patients only on anthracycline treatment (Figure 3 ). The cumulative incidence of occurrence of HF at 3 years was 19.6% (95% CI, 16.8-22.4) in patients on trastuzumab therapy compared with 1% (95% CI, 0.9-1.4) in counterparts not on trastuzumab. Baseline LVS measurement was also associated with new HF events (HR, 3.4 [95% CI, 1.5-7.9]; P=0.004 per unit). Table 4 summarizes multivariable models emphasizing the independence of the effect of BB treatment from a variety of potential confounders. These models emphasize the robustness of the independent association between BB treatment and 
Discussion
The success of modern therapy for breast cancer has created a cohort of survivors who are at risk of the development of HF. The results of this study emphasize the development of HF, especially in patients treated with trastuzumab, with or without preceding anthracycline therapy, and the associations of this therapy with incident HF. β-adrenoceptor blockade seems to be protective against incident HF in patients receiving trastuzumab. Several pathophysiological mechanisms have been previously proposed.
Cardiotoxicity and Trastuzumab
The amplification of the EHR2/neu (ErbB2) gene represents a pivotal modification in a subgroup of patients with very aggressive breast cancer. Trastuzumab (herceptin) is a humanized monoclonal antibody against the EHR2 protein that has been shown to substantially reduce the risk of recurrence and early death in women with EHR2-positive breast cancers. However, studies of mutant mouse models have documented an essential role of the erbB2 gene in the embryonic and postnatal heart. In mice that are deficient in ErbB2 protein, the induction of cardiac stress pathways by either hemodynamic overload or cardiotoxicity (eg, attributable to anthracycline) promotes the onset of LV dysfunction. 20 The basis for this toxicity is the fundamental role of the ErbB2-ErbB4 heterodimeric receptors in triggering the myocyte-survival pathways that are required during the activation of acute stress signals. The loss of these pathways after trastuzumab treatment can lead to irreversible loss of cardiac myocytes during exposure to anthracycline. These observations are consistent with the clinical finding that trastuzumab increases the risk of cardiac side-effects in patients with existing forms of heart disease in which the cardiac stress signals are presumably already activated.
Initial reports of the cardiotoxicity of trastuzumab emphasized this entity as a benign, echocardiographic, and reversible finding. Indeed, type II chemotherapy-related cardiac dysfunction was described as an entity to characterize unique features (eg, lack of a dose relationship, absence of identifiable structural changes, high likelihood of recovery in 2 to 4 months, and low likelihood of subsequent stress-related cardiac dysfunction), which distinguish it from the classical myocardial damage caused by doxorubicin. 3 However, subsequent analyses have not supported this benign perspective. In an analysis of the National Surgical Adjuvant Breast and Bowel project B-31, Telli et al 10 showed that 71% of patients had a sustained decrease in LVEF relative to baseline, when evaluated at >6 months of follow-up, causing 14% of them to discontinue therapy because of asymptomatic LV dysfunction. Of the patients that developed cardiotoxicity, more than two thirds continued to receive cardiac medications. More recently, Cardinale et al 4 confirmed that 40% of patients failed to recover from trastuzumabinduced cardiomyopathy, causing a significant impact in their rate of major adverse cardiac events. LVEF recovery occurred less frequently in troponin-positive patients, who were characterized by anthracycline therapy. The findings of our study support these latter observations and raise important concern for the prognosis of this population. Our observations also emphasize the independence of trastuzumab effects from previous administration of anthracycline.
Cardioprotection With Chemotherapy
The high rate of discontinuation of therapy, with its impact in cancer mortality, along with the evidence of significant cardiac morbidity in the untreated population, makes the use of cardioprotective agents highly desirable. Although advances have been made in reducing the cardiotoxicity of anthracycline therapy, 21 the most appropriate strategy for avoidance of trastuzumab cardiotoxicity is undefined. Effective strategies have been made in the early treatment of anthracycline cardiomyopathy, 4 but the development of a preventive strategy would be preferable.
Cardinale et al 22 have described mitigation of anthracyclineinduced cardiotoxicity with the administration of ACE inhibitors. There was no evidence of cardioprotective effects of ACE inhibitors in this population that received anthracycline followed by trastuzumab, although an effect may have been hidden by small numbers and the matching process.
Previously published data from a small series have shown cardioprotective effect of BBs in anthracycline-induced cardiomyopathy. 23 However, to our knowledge, the demonstration of a protective effect associated with use of BBs at the onset of treatment with trastuzumab in this study is the first to suggest beneficial effect of BBs in this situation. The cellular mechanism by which BBs provided cardioprotection in this setting is not known. Although different BBs have varying antioxidant effects, it seems plausible that this cardioprotective effect may be rooted in the effect of the human epidermal growth factor receptor in cardioprotection and the documented relationship between afterload and LV dysfunction attributable to trastuzumab. 24 Nonetheless, it is important to recognize that the titration of BBs may not be an easy task in patients actively receiving chemotherapy, with its secondary side-effects. It is unclear whether the optimal strategy should be to treat all at-risk patients, or to screen patients for subclinical dysfunction and treat those at high risk of toxicity. The optimal method for the selection of at-risk patients remains to be determined.
Limitations
This is an observational study, with information obtained from EHR. This material was gathered prospectively into templates in the record and validated by a process of including HF admissions mentioned in subsequent records and review of the original record, both of which we have found to improve the specificity of using HF admission as an end point.
In an observational data set such as this, pretreatment with BBs could introduce confounding by indication. This leads to a risk of erroneous associations, for example, older age seems to be associated with a lower risk of incident HF. This univariable association is likely confounded by the fact that the average age of BB-treated patients was 57 years and nontreated patients was 52 years; therefore, older patients were more likely to be on cardioprotective therapy. Nonetheless, the primary comorbidity for which BB is indicated would be expected to augment rather than reduce HF risk, and we also accounted for baseline differences between treated and untreated patients using a propensity score. The sample of patients receiving BBs was too small to perform stratified analysis based on other patient characteristics, which might have impacted the overall observed benefit of use of BBs or undetected potential benefits of other medication previously recognized as cardioprotective, including ACE inhibitors. Larger samples will be needed to determine the benefits of use of BBs in preventing HF (including the merits, if any, of specific agents) and the relationship between short-term markers of cardiac dysfunction and HF. Patients who survive cancer are at increased risk of developing cardiovascular disease. The use of anthracycline and trastuzumab, especially in combination, poses a specific risk for the development of heart failure (HF). Routine evaluation is performed before and during therapy, but the appropriate management of asymptomatic mild left ventricular dysfunction in patients without known cardiovascular disease at the time of cancer treatment onset is unclear. Although use of cardioprotective agents has been suggested, neither intentional nor coincidental continuous use of β-blocker agents (BBs) during trastuzumab and chemotherapy treatment has yet been studied. We hypothesized that continuous incidental use of BBs was protective against HF. From a pool of 920 consecutive patients with breast cancer (age 52.3±11.0 years) with normal ejection fraction before receiving trastuzumab and anthracycline therapy at our institution between 2005 and 2010, we compared 106 patients on continuous BBs during cancer treatment with 212 matched patients from the same pool with similar characteristics but not on continuous BBs. During a median follow-up of 3.2±2.0 years, 32 incident HF admissions were identified, and 28 cancer-related (noncardiac) deaths occurred before any incident HF. Coincidental, continuous use of BBs is associated with lower incidence of HF in patients with breast cancer (hazard ratio, 0.2; 95% confidence interval, 0.1-0.5; P=0.003). A prospective randomized clinical trial to validate the cardioprotective effect of β-blockade in patients receiving anthracycline and trastuzumab seems warranted.
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